MFDS Approves GSK's Targeted Treatment for Endometrial Cancer, 'Zemperi-joo'
[Asia Economy Reporter Jo In-kyung] The Ministry of Food and Drug Safety announced on the 14th that it has approved GlaxoSmithKline's new drug for endometrial cancer treatment, Gemperizoo (Dostarlimab).
Gemperizoo is a monoclonal antibody targeting the immune checkpoint receptor programmed cell death protein 1 (PD-1) on immune cells (T cells). It blocks the mechanism by which cancer cells use PD-1 to evade attacks from immune cells (T cells), helping immune cells eliminate cancer cells.
Hot Picks Today
Samsung Electronics Introduces New "Special Performance Bonus" for Semiconductors, Paid Entirely in Company Shares
- "Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- Will Soaring Semiconductor Prices Support a Gradual Stabilization of the Household Debt Ratio? Why [BOK Focus]
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
The Ministry of Food and Drug Safety stated, "We will continue to do our best to ensure that treatments with confirmed safety and efficacy are supplied promptly, based on regulatory science."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
